Met Based Drugs. 2008;2008:469531. doi: 10.1155/2008/469531.

Synthetic polymers as drug-delivery vehicles in medicine.

Metal-based drugs

Eberhard W Neuse

PMID: 18497867 PMCID: PMC2386871 DOI: 10.1155/2008/469531

Abstract

Cancerous diseases present a formidable health problem worldwide. While the chemotherapy of cancer, in conjunction with other treatment modalities, has reached a significant level of maturity, efficacious use of such agents is still restricted by numerous pharmacological deficiencies, such as poor water solubility, short serum circulation lifetimes, and low bioavailability resulting from lack of affinity to cancer tissue and inadequate mechanisms of cell entry. More critically still, most drugs suffer from toxic side effects and a risk of drug resistance. The class of platinum anticancer drugs, although outstandingly potent, is particularly notorious in that respect. Among the countless methods developed in recent years in an effort to overcome these deficiencies, the technology of polymer-drug conjugation stands out as a particularly advanced treatment modality. The strategy involves the bioreversible binding, conjugating, of a medicinal agent to a water-soluble macromolecular carrier. Following pharmacokinetic pathways distinctly different from those of the common, nonpolymeric drugs, the conjugate so obtained will act as a prodrug providing safe transport of the bioactive agent to and into the affected, that is, cancerous cell for its ultimate cell-killing activity. The present treatise will acquaint us with the pharmacological fundamentals of this drug delivery approach, applied here specifically to the metalorganic platinum-type drug systems and the organometallic ferrocene drug model. We will see just how this technology leads to conjugates distinctly superior in antiproliferative activity to cisplatin, a clinically used antitumor agent used here as a standard. Polymer-drug conjugation involving metal-based and other medicinal agents has unquestionably matured to a practical tool to the pharmaceutical scientist, and all indications point to an illustrious career for this nascent drug delivery approach in the fight against cancer and other human maladies.

References

1. Adv Drug Deliv Rev. 2003 Feb 24;55(3):421-37 - PubMed
2. J Drug Target. 2006 Jul;14(6):391-403 - PubMed
3. Prog Med Chem. 1987;24:129-58 - PubMed
4. Anticancer Res. 2001 May-Jun;21(3B):2033-7 - PubMed
5. Clin Cancer Res. 2004 May 15;10(10):3386-95 - PubMed
6. Ann N Y Acad Sci. 1987;507:1-364 - PubMed
7. Nat Rev Drug Discov. 2003 May;2(5):347-60 - PubMed
8. J Drug Target. 2002 Nov;10(7):549-56 - PubMed
9. Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 - PubMed
10. Farmaco. 1999 Aug 30;54(8):497-516 - PubMed
11. J Control Release. 2003 Feb 21;87(1-3):89-105 - PubMed
12. J Control Release. 2000 Mar 1;65(1-2):271-84 - PubMed
13. Eur J Cancer. 2004 Jan;40(2):291-7 - PubMed
14. Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):1-22 - PubMed
15. Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 - PubMed
16. Nat Rev Drug Discov. 2005 Jul;4(7):581-93 - PubMed
17. Eur J Pharm Sci. 2003 Sep;20(1):1-16 - PubMed
18. Expert Opin Investig Drugs. 1998 Nov;7(11):1849-64 - PubMed
19. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99 - PubMed
20. J Med Chem. 1973 Aug;16(8):893-7 - PubMed

Publication Types

• Journal Article